Shenzhen YHLO Biotech (688575) Fundamentals 2026 — P/E 128.7x, Revenue Analysis | SniperIQ
Shenzhen YHLO Biotech (688575) is a CN-listed Healthcare company in Medical - Specialties with a market capitalization of ¥5.1B, trading at ¥9.01 on the SHH. This SniperIQ fundamentals page covers Shenzhen YHLO Biotech's valuation (P/E 128.7x, P/B 1.9x), profitability (net margin 1.8%), revenue (¥1.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shenzhen YHLO Biotech's market cap?
Shenzhen YHLO Biotech (688575) has a market capitalization of approximately ¥5.1B, trading at ¥9.01 on the SHH. Market cap moves with the live share price.
What is Shenzhen YHLO Biotech's P/E ratio?
Shenzhen YHLO Biotech's trailing twelve-month P/E ratio is 128.7x, with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shenzhen YHLO Biotech?
Shenzhen YHLO Biotech runs a net profit margin of 1.8%, a gross margin of 101.1%, and an operating margin of 7.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shenzhen YHLO Biotech generate?
Shenzhen YHLO Biotech reported revenue of ¥1.8B for fiscal year 2025, with net income of ¥23M and earnings per share (EPS) of 0.04. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shenzhen YHLO Biotech pay a dividend?
Shenzhen YHLO Biotech offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shenzhen YHLO Biotech financially healthy?
Shenzhen YHLO Biotech carries a debt-to-equity ratio of 0.36x and a current ratio of 2.19x, with a market beta of 0.17. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shenzhen YHLO Biotech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shenzhen YHLO Biotech (688575) the key facts are: market cap ¥5.1B, P/E 128.7x, revenue ¥1.8B, 52-week range 8.34-17. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shenzhen YHLO Biotech's full fundamentals live
Get Shenzhen YHLO Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.